Serina Therapeutics, Inc.

Part of Lineage Cell Therapeutics, Inc.

UEI
EJRNPKNUBNM8
CAGE
80JU0
Primary NAICS
Not on record
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Website
agexinc.com
Founded
2017
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Serina Therapeutics, Inc.'s 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Novel highly regenerative and scalable progenitor cell exosomes for treating peripheral artery disease - abstract… Grant · R41HL170875 National Heart Lung and Blood Institute $323,002
Metabolically reprogrammed mesenchymal stem cells for treating osteoporosis Grant · R43AR074351 National Insititue of Arthritis and Musculoskeletal and Skin Diseases $224,973
Novel highly regenerative and scalable progenitor cell exosomes for treating stroke Grant · R41NS105263 National Institute of Neurological Disorders and Stroke $385,923

Quick answers

What is Serina Therapeutics, Inc.'s UEI?

Serina Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is EJRNPKNUBNM8.

What is Serina Therapeutics, Inc.'s CAGE code?

Serina Therapeutics, Inc.'s CAGE code is 80JU0.

Is Serina Therapeutics, Inc. registered in SAM.gov?

Serina Therapeutics, Inc.'s SAM.gov registration expired on July 30, 2025.

Who is Serina Therapeutics, Inc.'s parent company?

Serina Therapeutics, Inc. is part of Lineage Cell Therapeutics, Inc.

What is Serina Therapeutics, Inc.'s most recent federal award?

Serina Therapeutics, Inc.'s most recent federal grant award is Novel highly regenerative and scalable progenitor cell exosomes for treating peripheral artery disease - abstract… (R41HL170875), from National Heart Lung and Blood Institute, on September 1, 2023.

On GovTribe

See Serina Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login